In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 records · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Liraglutide | ||
|---|---|---|---|
| Identity | |||
| Kind | Small molecule | Synthetic analog | |
| Area | Weight and metabolic | Weight and metabolic | |
| Evidence | |||
| Amount of evidence | 340 | 4,766 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 121 (119 in people) | 805 (793 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 53 · 20 active1 more mentions it but does not test it | 469 · 30 active49 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Foundayo says: “With a reduced-calorie diet and increased physical activity: reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight in the presence of at least one weight-related comorbid condition” No central EU authorisation (EMA).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Orforglipron | Liraglutide |
|---|---|---|
| Glycemic controlMetabolic and weight | 54513 | 1,1171067491 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The EMA label for Victoza says: “Adults, adolescents and children 10 years and older with insufficiently controlled type 2 diabetes, as an adjunct to diet and exercise”
| Body weightMetabolic and weight | 66633 | 83481717 |
|---|
| Adverse eventsWhole body | 545211 | 50449311 |
|---|
| Gastrointestinal adverse eventsGastrointestinal | 4646 | 185185 |
|---|
| Heart functionCardiovascular | 66 | 214198142 |
|---|
| LipidsMetabolic and weight | 13121 | 14313733 |
|---|
| Liver fat and liver functionLiver | 99 | 1361279 |
|---|
| Cardiovascular eventsCardiovascular | 211 | 13313111 |
|---|
| PharmacokineticsPharmacology | 383332 | 969231 |
|---|
| Blood pressureCardiovascular | 66 | 1201182 |
|---|
| Inflammation markersImmune and inflammation | 413 | 117100152 |
|---|
| Appetite and food intakeMetabolic and weight | 33 | 1129517 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Liraglutide differs from Glucagon-like peptide 1 (7-37) at 1 position and carries 1 added group.
What is different
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 53 trials, ranked by phase, then posted results and enrollment: 1 ongoing · 2 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Eli Lilly and Company3,127 participants5 Jun 2023 to est. Oct 2027
Obesity · Overweight · Overweight or Obesity
Eli Lilly and Company1,698 participants22 Sept 2023 to 22 Aug 2025
Type 2 Diabetes
Eli Lilly and Company1,613 participants5 Jun 2023 to 8 Aug 2025
Obesity · Overweight · Type 2 Diabetes
1 more mentions it but does not test it. They only measure it or name it in their text.
Top 3 of 469 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S9,341 participants31 Aug 2010 to 17 Dec 2015
Diabetes · Diabetes Mellitus, Type 2
GRADE Study Group7,850 participantsMay 2013 to 30 Apr 2021
Type 2 Diabetes · Comparative Effectiveness of Glycemia-lowering Medications
Novo Nordisk A/S3,731 participants1 Jun 2011 to 2 Mar 2015
Metabolism and Nutrition Disorder · Obesity
49 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Orforglipron | Liraglutide |
|---|---|---|
| Body weightMetabolic and weightCompared as: value in the arm that got the peptide, in % | −8.6 to −12.6% Weight change Placebo: −2% Dose studied: 12, 24, 36, or 45 mg once daily26 weeksn = 2722023 | −5.8% Mean weight change · liraglutide 3.0 mg Placebo: −1.5% Dose studied: 3.0 mg56 weeksn = 3962020 |
| Glycemic controlMetabolic and weightCompared as: difference from placebo, in % | −1.08% Estimated treatment difference in HbA1c vs placebo Dose studied: 12 mg once daily40 weeksn not reported2026 | |
| Gastrointestinal adverse eventsGastrointestinalCompared as: value in the arm that got the peptide, in % | 62.1% Gastrointestinal adverse events Dose studied: Maximum tolerated dose up to 36 mg capsule, equivalent to 17.2 mg tablet, once dailyMedian follow-up of 2 yearsn = 2,7262026 | 82.7% |
| Adverse eventsGastrointestinalCompared as: value in the arm that got the peptide, in % | 81.5 to 92.5% 95% confidence interval for TEAE percentage · orforglipron 36 mg Dose studied: 36 mg once daily52 weeksn = 2692026 | 7.9% |
| Heart functionCardiovascularCompared as: value in the arm that got the peptide, in bpm | 3.7 bpm Mean increase in pulse rate · orforglipron 12 mg Dose studied: 12 mg52 weeksn not reported2026 |
−8.6 to −12.6%
Weight change
Placebo: −2%
Dose studied: 12, 24, 36, or 45 mg once daily26 weeksn = 2722023
−5.8%
Mean weight change · liraglutide 3.0 mg
Placebo: −1.5%
Dose studied: 3.0 mg56 weeksn = 3962020
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Orforglipron | Liraglutide |
|---|---|---|
| Treatment adherence and retentionWhole bodyCompared as: value in the arm that got the peptide, in % | No comparable result 1 randomized-trial result measure it in another way or another unit. | 65% Trial completion Placebo: 53.4% Dose studied: 3.0 mg/d56 weeks |
−1.09%
HbA1c difference
Dose studied: 1.8 mg once daily26 weeksn = 3442009
Gastrointestinal adverse events · liraglutide 3.0 mg
Dose studied: 3.0 mg once daily68 weeksn = 1272022
Discontinuation due to adverse events
Dose studied: up to 1.8 mg/dup to 104 weeksn = 1,9912022
6.4 bpm
Pulse change
Placebo: −0.9 bpm
Dose studied: 1.8 mg14 weeksn not reported2013
−1.08%
Estimated treatment difference in HbA1c vs placebo
Dose studied: 12 mg once daily40 weeksn not reported2026
−1.09%
HbA1c difference
Dose studied: 1.8 mg once daily26 weeksn = 3442009
62.1%
Gastrointestinal adverse events
Dose studied: Maximum tolerated dose up to 36 mg capsule, equivalent to 17.2 mg tablet, once dailyMedian follow-up of 2 yearsn = 2,7262026
82.7%
Gastrointestinal adverse events · liraglutide 3.0 mg
Dose studied: 3.0 mg once daily68 weeksn = 1272022
81.5 to 92.5%
95% confidence interval for TEAE percentage · orforglipron 36 mg
Dose studied: 36 mg once daily52 weeksn = 2692026
7.9%
Discontinuation due to adverse events
Dose studied: up to 1.8 mg/dup to 104 weeksn = 1,9912022
3.7 bpm
Mean increase in pulse rate · orforglipron 12 mg
Dose studied: 12 mg52 weeksn not reported2026
6.4 bpm
Pulse change
Placebo: −0.9 bpm
Dose studied: 1.8 mg14 weeksn not reported2013
| Inflammation markersImmune and inflammationCompared as: difference from placebo, in ng/ml | No comparable result 1 randomized-trial result measure it in another way or another unit. | 14.9 ng/ml Serum NGAL difference Dose studied: 3 mg/d52 weeksn = 1272025 |
|---|
| LipidsCardiovascularCompared as: difference from placebo, in lipids | No comparable result 7 randomized-trial results measure it in another way or another unit. | 21 lipids Lipids decreased 26 weeksn = 1022021 |
|---|
| Cardiometabolic risk factorsMetabolic and weightCompared as: difference from placebo, in % | No comparable result 1 randomized-trial result measure it in another way or another unit. | −4% MR-proADM reduction · Shown as a change. The study reports a mr-proadm reduction of this size. Dose studied: 1.8 mg/d12 weeksn = 272017 |
|---|
| Receptor activity and mechanismCardiovascularCompared as: difference from placebo, in proteins | No comparable result 1 randomized-trial result measure it in another way or another unit. | 124 proteins Proteins modulated Dose studied: 3 mg daily5 weeksn = 202026 |
|---|
| PharmacokineticsPharmacologyCompared as: difference from placebo, in minutes | No comparable result 14 randomized-trial results measure it in another way or another unit. | 15 minutes tmax delay Dose studied: 1.8 mgn = 182011 |
|---|
| Vascular functionCardiovascularCompared as: value in the arm that got the peptide, in % | No randomized trial result 1 result from other study designs. | −8.6% PWV decrease · Shown as a change. The study reports a pwv decrease of this size. 12 monthsn = 802020 |
|---|
No comparable result
1 randomized-trial result measure it in another way or another unit.
65%
Trial completion
Placebo: 53.4%
Dose studied: 3.0 mg/d56 weeksn = 1322025
No comparable result
1 randomized-trial result measure it in another way or another unit.
14.9 ng/ml
Serum NGAL difference
Dose studied: 3 mg/d52 weeksn = 1272025
No comparable result
7 randomized-trial results measure it in another way or another unit.
21 lipids
Lipids decreased
26 weeksn = 1022021
No comparable result
1 randomized-trial result measure it in another way or another unit.
−4%
MR-proADM reduction · Shown as a change. The study reports a mr-proadm reduction of this size.
Dose studied: 1.8 mg/d12 weeksn = 272017
No comparable result
1 randomized-trial result measure it in another way or another unit.
124 proteins
Proteins modulated
Dose studied: 3 mg daily5 weeksn = 202026
No comparable result
14 randomized-trial results measure it in another way or another unit.
15 minutes
tmax delay
Dose studied: 1.8 mgn = 182011
No randomized trial result
1 result from other study designs.
−8.6%
PWV decrease · Shown as a change. The study reports a pwv decrease of this size.
12 monthsn = 802020